<DOC>
	<DOCNO>NCT02751307</DOCNO>
	<brief_summary>Metformin use alleviate metabolic abnormality patient schizophrenia . Until , low dose metformin treat metabolic abnormality clozapine-treated patient 1000 mg/d . The aim study determine whether low dosage metformin , 500 mg/d , effective improve metabolic profile clozapine-treated patient pre-existing metabolic abnormality . Methods : In 12-week , randomize , double-blind , placebo-controlled trial , metformin 500 mg/d 1000 mg/d placebo prescribe clozapine-treated patient schizophrenia pre-existing metabolic abnormality . The recruited patient underwent physical laboratory evaluation week-4 , week-8 , week-12 .</brief_summary>
	<brief_title>Adjunctive Low-dose Metformin Patients With Schizophrenia Metabolic Abnormalities</brief_title>
	<detailed_description>Methods In 12-week , randomize , double-blind , placebo-controlled trial , metformin 500 mg/d 1000 mg/d placebo prescribe clozapine-treated patient schizophrenia pre-existing metabolic abnormality . The study approve institutional review board conduct Taipei Medical University-Wan Fang Hospital Taipei City Psychiatric Center May 2013 January 2015 . All clinical investigation conduct accord principle express Declaration Helsinki . The investigator screen clozapine-treated patient first phase enrol eligible patient clinical trial . Written inform consent obtain patient screen . Patients first-phase screening Patients diagnose schizophrenia schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ; age 20-65 year ; take clozapine least 3 month invite first-phase screening . Clinical interview conduct , medical record evaluate collect patient demographic clinical information , namely diagnosis , age onset , dosage clozapine use . Measurements The height , BW , waist circumference ( WC ) , blood pressure ( BP ) patient measure . The body mass index ( BMI ) calculate BW kilogram divide square height meter . After overnight fasting , blood collect analyze fast plasma glucose ( FPG ) , TG , high-density lipoprotein cholesterol ( HDL-C ) level . Under manufacture 's guide , fast TG , FPG , HDL-C level measure use automated system ( Roche Cobas C501 ) . Patients metformin trial Patients first-phase screen enrolled present trial least one follow metabolic abnormality : BMI ≥ 24 ; WC &gt; 90 cm ( men ) 80 cm ( woman ) ; fast serum TG level ≥ 150 mg/dL ; fast serum HDL-C level ≤ 40 mg/dL ( men ) 50 mg/dL ( woman ) ; systolic BP ≥ 130 diastolic BP ≥ 85 mm Hg ; current use antihypertensive agent ; FPG level = 100-126 mg/dL . The exclusion criterion follow : history diabetes mellitus ( DM ) ; current use hypoglycemic hypolipidemic agent ; pregnancy ; allergy metformin ; creatinine level &gt; 1.4 ng/dL ; abnormal liver function test result ; chronic cardiopulmonary insufficiency . Trial procedure Patients recruit trial randomize three group , metformin 500 mg/d , metformin 1000 mg/d , placebo . The randomization conduct research assistant , blind patient 's status . To ensure concealment randomization , metformin placebo provide coded container . The appearance placebo identical metformin tablet . All patient , caregiver , investigator mask randomization . In first week , 500 mg metformin administer morning group metformin 500 mg/d 1000 mg/d , placebo administer placebo group . In second week , dosage revise 500 mg metformin morning placebo even group metformin 500 mg/d , 500 mg metformin twice day group metformin 1000 mg/d , placebo twice daily placebo group . For patient , clozapine dosage remain unchanged throughout intervention . The recruited patient underwent physical laboratory evaluation week-4 , week-8 , week-12 . Statistical analyse The investigator use descriptive statistic summarize baseline clinical characteristic patient analysis variance examine difference characteristic among group . Patients continue intervention least 4 week include analysis . The investigator adopt last observation carry forward ( LOCF ) approach replace miss data , assume change miss value metabolic index event dropout . Furthermore , investigate whether repeat measure collect longitudinal manner change time , investigator first use paired test examine difference baseline follow-up measure . Repeated measure analyse conduct use 2-way within-subjects analysis variance examine group ( df = 2 , group ) , time ( df = 3 , within subject ) , interaction ( df = 6 , interaction time group ) effect change metabolic profile time . The analysis conduct use SPSS Version 20.0 ( IBM , Armonk , NY ) . P &lt; 0.05 consider indicate statistical significance .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>1. patient diagnose schizophrenia schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition 2. age 2065 year 3. take clozapine least 3 month 4. least one follow metabolic abnormality : BMI ≥ 24 ; WC &gt; 90 cm ( men ) 80 cm ( woman ) ; fast serum TG level ≥ 150 mg/dL ; fast serum HDLC level ≤ 40 mg/dL ( men ) 50 mg/dL ( woman ) ; systolic BP ≥ 130 diastolic BP ≥ 85 mm Hg ; current use antihypertensive agent ; FPG level = 100126 mg/dL . 1. history diabetes mellitus 2. current use hypoglycemic hypolipidemic agent 3. pregnancy 4. allergy metformin 5. creatinine level &gt; 1.4 ng/dL 6. abnormal liver function test result 7. chronic cardiopulmonary insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>metformin</keyword>
	<keyword>clozapine</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>metabolic trait</keyword>
</DOC>